ES2721178T3 - Firma molecular de manchas cutáneas pigmentarias, asociada con la organización de la matriz extracelular - Google Patents

Firma molecular de manchas cutáneas pigmentarias, asociada con la organización de la matriz extracelular Download PDF

Info

Publication number
ES2721178T3
ES2721178T3 ES12722444T ES12722444T ES2721178T3 ES 2721178 T3 ES2721178 T3 ES 2721178T3 ES 12722444 T ES12722444 T ES 12722444T ES 12722444 T ES12722444 T ES 12722444T ES 2721178 T3 ES2721178 T3 ES 2721178T3
Authority
ES
Spain
Prior art keywords
organization
extracellular matrix
spot
molecular signature
skin spots
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12722444T
Other languages
English (en)
Inventor
Françoise Bernerd
Christine Duval
Lacharriere Olivier De
Stéphanie Nouveau
Xavier Marat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1153535A external-priority patent/FR2974372B1/fr
Priority claimed from FR1153534A external-priority patent/FR2974371B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of ES2721178T3 publication Critical patent/ES2721178T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Birds (AREA)

Abstract

Método de caracterización de una mancha pigmentaria cutánea aparente o sospechosa en un ser humano, que comprende comparar los niveles de expresión, en muestras de piel resultante de dicha mancha y de piel adyacente intacta, dentro de las células de la dermis, de al menos un gen dérmico implicado en la organización de la matriz extracelular, seleccionado entre la lista constituida por los genes MXRA5, LYZ, CTSL2, PLAU y TIMP1, en el que dicha mancha pigmentaria cutánea es un léntigo actínico, senil o solar.
ES12722444T 2011-04-22 2012-04-20 Firma molecular de manchas cutáneas pigmentarias, asociada con la organización de la matriz extracelular Active ES2721178T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1153535A FR2974372B1 (fr) 2011-04-22 2011-04-22 Signature moleculaire des taches pigmentaires cutanees, associee au remodelage de la matrice extracellulaire
FR1153534A FR2974371B1 (fr) 2011-04-22 2011-04-22 Signature moleculaire des taches pigmentaires cutanees, associee a la famille des proteoglycanes et glycoproteines extracellulaires
US201161494443P 2011-06-08 2011-06-08
US201161494447P 2011-06-08 2011-06-08
PCT/FR2012/050861 WO2012172221A2 (fr) 2011-04-22 2012-04-20 Signature moléculaire des taches pigmentaires cutanées, associée à l'organisation de la matrice extracellulaire

Publications (1)

Publication Number Publication Date
ES2721178T3 true ES2721178T3 (es) 2019-07-29

Family

ID=47357543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12722444T Active ES2721178T3 (es) 2011-04-22 2012-04-20 Firma molecular de manchas cutáneas pigmentarias, asociada con la organización de la matriz extracelular

Country Status (7)

Country Link
US (1) US20140044799A1 (es)
EP (1) EP2699222B1 (es)
JP (1) JP6223960B2 (es)
KR (1) KR102106374B1 (es)
CN (1) CN103619317B (es)
ES (1) ES2721178T3 (es)
WO (1) WO2012172221A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014207874A (ja) * 2013-03-28 2014-11-06 ポーラ化成工業株式会社 肌の色調改善剤のスクリーニング法
GB2534879A (en) * 2015-02-03 2016-08-10 Stratton Richard The identification of genomic markers in the first intron of the LEPREL 1 gene which predict resistance or susceptibilty to fibrotic disorders
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
KR101971358B1 (ko) * 2016-09-26 2019-04-23 동국대학교 산학협력단 검버섯 진단용 마커로서의 구아닌 탈아미노효소의 용도
CN108492278B (zh) * 2018-02-09 2019-08-16 武汉嫦娥医学抗衰机器人股份有限公司 人体皮肤片图像黑色素和血色素分离与浓度调控方法
KR102117504B1 (ko) * 2018-07-23 2020-06-01 아주대학교산학협력단 Sdf1 프로모터 영역을 이용한 피부 미백제 스크리닝 방법
CN109761650A (zh) * 2019-01-30 2019-05-17 马春江 一种农家肥微量元素组分提取工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070065665A (ko) * 2005-12-20 2007-06-25 주식회사 엘지생활건강 미백 화장료 조성물
JP2007289063A (ja) * 2006-04-25 2007-11-08 Shiseido Co Ltd しみ部位亢進遺伝子群を指標とした皮膚しみ形成予知方法、皮膚しみ形成抑制剤のスクリーニング方法
EP2152911A4 (en) * 2007-05-04 2010-05-19 Dermtech Int DIAGNOSIS OF MELANOMA BY NUCLEIC ACID ANALYSIS
CN101574357A (zh) * 2008-05-05 2009-11-11 天津天士力制药股份有限公司 三七皂苷r1对微循环障碍引发的疾病的预防和治疗
CN102089444A (zh) * 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
KR101109739B1 (ko) * 2009-01-08 2012-04-12 사회복지법인 삼성생명공익재단 멜라닌 과다 생성 검출용 마커 및 이의 용도
FR2946880B1 (fr) * 2009-06-22 2011-07-15 Oreal Composition contenant un extrait de bacterie filamenteuse et procede de traitement cosmetique des signes du vieillissement
FR2953220B1 (fr) * 2009-12-01 2012-11-23 Oreal Signature microarn de la differenciation epidermique et utilisations

Also Published As

Publication number Publication date
US20140044799A1 (en) 2014-02-13
CN103619317B (zh) 2017-06-09
EP2699222B1 (fr) 2019-02-06
KR20140024400A (ko) 2014-02-28
CN103619317A (zh) 2014-03-05
WO2012172221A3 (fr) 2013-03-28
JP6223960B2 (ja) 2017-11-01
EP2699222A2 (fr) 2014-02-26
WO2012172221A2 (fr) 2012-12-20
JP2014513526A (ja) 2014-06-05
KR102106374B1 (ko) 2020-05-04

Similar Documents

Publication Publication Date Title
ES2721178T3 (es) Firma molecular de manchas cutáneas pigmentarias, asociada con la organización de la matriz extracelular
Strait et al. Biological impact of auditory expertise across the life span: musicians as a model of auditory learning
AR080009A1 (es) Alteracion genomica objetivo utilizando nucleasas de dedos de zinc
JOP20210207B1 (ar) مركبات ترابطية مستهدفة
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
BRPI1009263A2 (pt) alfa-amilases relacionadas com cepa de bacillus megaterium dsm90 e métodos de uso das mesmas.
AR072531A1 (es) SENAL DE POLIADENILACIoN
CO2017003528A2 (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
Ptáčková et al. Evolution of Archamoebae: morphological and molecular evidence for pelobionts including Rhizomastix, Entamoeba, Iodamoeba, and Endolimax
BRPI0819649A2 (pt) método, organismo geneticamente modificado, e, célula de levedura recinbinante
EA201401319A1 (ru) Способы и композиции рнк-специфической модификации днк-мишении рнк-специфической модуляции транскрипции
UY34227A (es) Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo
EP3734281A3 (en) Therapeutic and diagnostic methods relating to cancer stem cells
BRPI0612301A2 (pt) mÉtodo para diagnosticar uma suscetibilidade para a diabete tipo ii em um indivÍduo, kit, e, mÉtodo para avaliar um indivÍduo quanto a probabilidade de resposta a um agente terapÊutico de tcf7l2
MX2009002936A (es) Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
WO2011138786A3 (en) Stem cell bank for personalized medicine
AR093799A1 (es) Gen plaguicida y uso del mismo
BR112012016437A2 (pt) fotobiorreator em meio fechado para a cultura de micro-organismos fotossintéticos.
AR100382A1 (es) Método para producir nailon
BR112012022238A2 (pt) pele artificial
CL2012002871A1 (es) Metodo para identificar una población de celulas tr1 en reposo que comprende la deteccion de la expresion en la superficie celular de los marcadores cd4, cd25, cd127 y cd62l; poblacion aislada de celulas tr1; metodo para disminuir una poblacion de celulas tr1; kit para identificar o aislar una poblacion de celulas tr1 en reposo y/o activadas; composicion farmaceutica que comprende una poblacion de celulas tr1 en reposo y/o activadas.
AR101477A1 (es) Composiciones y métodos para identificar y seleccionar plantas de maíz con resistencia al tizón norteño
ES2722900T3 (es) Portaobjetos para micromatrices y método para detectar algas tóxicas
Aon et al. On the network properties of mitochondria
BRPI0921371A2 (pt) Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.